mutations, in whom rituximab seems to get small extra value.59 Other genomic subgroups, for example patients with BIRC3 Environmental or self-antigens and homotypic interactions set off BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other indicators within the